ABSTRACT. Changes in the expression of the protein disulfide isomerase genes PDIA3 and PDIA6 may increase endoplasmic reticulum stress, leading to cellular instability and neoplasia. We evaluated the expression of PDIA3 and PDIA6 in invasive ductal carcinomas. Using reverse transcription-quantitative polymerase chain reaction, we compared the mRNA expression level in 45 samples of invasive ductal carcinoma with that in normal breast samples. Increased expression of the PDIA3 gene in carcinomas (P = 0.0009) was observed. In addition, PDIA3 expression was increased in tumors with lymph node metastasis (P = 0.009) and with grade III (P < 0.02). The PDIA6 gene showed higher expression levels in the presence of lymph node metastasis (U = 99.00, P = 0.0476) and lower expression for negative hormone receptors status (P = 0.0351). Our results suggest that alterations in PDIA3/6 expression 6961 PDIA3 and PDIA6 gene expression in ductal breast cancer ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (2): 6960-6967 (2015) levels may be involved in the breast carcinogenic process and should be further investigated as a marker of aggressiveness.
INTRODUCTION
Protein disulfide isomerases (PDIs) are responsible for the formation and isomerization of disulfide bonds, which function in protein folding. In addition, PDIs also act as chaperones, inhibiting the aggregation of unfolding substrates and/or assisting in the refolding of polypeptides (Wilkinson and Gilbert, 2004) .
The PDIA3 gene is highly expressed in response to cellular stress, as its product can function as a chaperone. It has also been linked to DNA repair as a member of the damage recognition complex and as a potential regulator that binds to genes with recognized repair functions (Chichiarelli et al., 2007) . Several studies have linked PDIs to different types of cancer, including gastric (Leys et al., 2007) , prostate (Pressinotti et al., 2009) , esophageal (Ayshamgul et al., 2011) , cervical (De Marco et al., 2012; Chung et al., 2013) , salivary gland (Müller et al., 2013) , bone metastasis (Santana-Codina et al., 2013) , and breast (Lee et al., 2012; Gaucci et al., 2013) cancers. Another gene in this superfamily, PDIA6, also encodes a product that exhibits chaperone activity by inhibiting misformed protein aggregation. The protein plays a role in platelet aggregation and activation by agonists such as convulxin, collagen, and thrombin. In addition, it interacts with polypeptide-related sequence A of class I major histocompatibility complex on the surface of tumor cells. This leads to a reduction in disulfide bonds with polypeptide-related sequence A of class I major histocompatibility complex, which is necessary for its release from tumor cells (Kaiser et al., 2007) .
In our previous study, we analyzed the proteome of ductal and lobular carcinomas, and PDIA3 and PDIA6 showed higher expressions levels in ductal than in lobular carcinomas (Oliveira et al., 2011) . Because of the high prevalence of invasive ductal carcinomas (IDC) among breast tumors, the importance of PDIs in protein folding and their relationship with proper cell function, we evaluated the correlation between expression of the PDIA3 and PDIA6 genes in patients with IDC and with their clinico-pathological parameters.
MATERIAL AND METHODS

Sample characterization
Forty-five primary IDC samples were collected during surgery at Hospital Nossa Senhora das Graças, Curitiba, south Brazil. Non-compromised tissues from the contralateral breast were obtained from 9 patients who underwent mammoplasty for simultaneous symmetrization. These tissues were analyzed by a pathologist and were considered to be normal. Tumor and normal samples were conserved in an RNA stabilization solution (RNAlater, Ambion Inc., Applied Biosystems, Foster City, CA, USA) immediately after surgery and were stored at 4°C. Clinicopathological data were obtained from the pathology service of the hospital. None of the patients had any family history of hereditary breast or ovarian cancer. The average age of the patients was 57.53 ± 16.39 years and that of the control group was 49.11 ± 10.43 years (P > 0.05). Patients had received neither chemotherapy nor radiation prior to surgery. LN = lymph node; G = histological grade; TS = tumor size; ER = estrogen receptor; PR = progesterone receptor; ERBB2 = amplification of the ERBB2 oncogene; P = presence of metastasis; A = absence of metastasis; NOS = not otherwise specified. 
Gene expression analysis
Total RNA was isolated using the RNAeasy extraction kit (Qiagen, Hilden, Germany). Next, 1200 ng total RNA was reverse-transcribed using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems).
Primers (Table 2) were designed using the PrimerBlast software (http://www.ncbi.nlm. nih.gov/tools/primer-blast/), using ideal conditions (Bustin et al., 2009 ) for reverse transcription-quantitative PCR. The ACTB and B2M genes were used as endogenous controls, selected using the TaqMan Human Endogenous Control Array microfluidic card (Applied Biosystems). Reaction efficiencies were determined using the Miner software (http://www.miner.ewindup. info/). The reverse transcription-quantitative PCR was performed using RealPlex equipment (Eppendorf, Hamburg, Germany). In this experiment, 15 ng cDNA, 2 pmol of each primer, and 5 mL Sybr Green PCR Master Mix (Applied Biosystems) were used in a total volume of 10 mL. The PCR program was as follows: 2 min at 50°C, 10 min at 95°C (initial denaturation), 15 s at 95°C, and 1 min at the annealing temperature, repeated 40 times (amplification). The PCR was evaluated by melting curve analysis following manufacturer instructions. 
Statistical analysis
Gene expression analysis was performed using the 2 -DDCt method relative to the selected controls, corrected for efficiency of amplification as previously described (Livak and Schmittgen, 2001) . The c 2 test was used to evaluate the homogeneity of the reference gene data. Further, we tested normality between groups. The Student t-test was used when the data showed a normal distribution; otherwise the nonparametric Mann-Whitney (U) test was applied. The significance of differences between the means of the expression between groups was analyzed using GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA). The significance threshold was considered to be 5%.
RESULTS
Evaluation of PDIA3 and PDIA6 gene expression
DDCt values were obtained for each sample tested for the PDIA3 and PDIA6 genes and normalized in relation to the reference genes. The normalized value was compared with the expression of a calibrator (1 stable sample chosen from the control group). Data are reported as the fold changes in gene expression (2 -DDCt ) relative to a calibrator sample (Livak and Schmittgen, 2001) . Table 3 and Figures 1-4 summarize the relative expression levels observed.
Our results showed that the PDIA3 gene contributes significantly to breast carcinogenesis compared with the PDIA6 gene, showing differential expression between IDC and normal tissue, as well as in most tumor subgroups. PDIA6 was differentially expressed in 2 tumors subgroups (LN metastasis and HR), suggesting a role in disease progression as well. IDC = invasive ductal carcinoma; NT = non-tumoral; LN = lymph node; ER+/PR+ = positive estrogen and progesterone receptors; ER-/PR-= negative estrogen and progesterone receptors; FC = fold change; N = sample number. 
DISCUSSION
PDIs are primarily found in the endoplasmic reticulum (involved in protein folding) and are linked to cancer invasion and migration (Lee et al., 2012) . Pressinotti et al. (2009) studied nearly 1200 genes using cDNA microarray in microdissected cell populations of lowand high-risk prostate tumors and found an association between high expression of PDIA3 and malignant stages. Our results in breast cancer agree with this observation, as overexpression of PDIA3 was observed in samples from patients with lymph node metastasis and grade III tumors. In addition, PDIA6 was overexpressed in samples from patients with lymph node metastasis, corroborating the hypothesis that higher expression of PDIs is linked to neoplastic progression (Bernardini et al., 2005) . Khan et al. (2004) , using a promyelocytic leukemia/ retinoic acid receptor a fusion in promyelocytic leukemia, and demonstrated that the resulting aberrant protein is recruited to the endoplasmic reticulum by binding to PDI. This mechanism suggests a link between protein quality control and neoplastic transformation, and indicates that new alternative therapeutic approaches can be developed to promyelocytic leukemia and other cancers by targeting these molecules (including PDI). Considering the large number of chromosome aberrations in cancer cells, PDIs have an important role in directing aberrant proteins to the endoplasmic reticulum. PDI3 was also associated with chemoprevention, as its expression was up-regulated in chemosensitive ovarian tumors when compared to chemoresistant tumors (Krynetskaia et al., 2009 ). Krynetskaia et al. (2009) reported an increased resistance of lung and renal carcinomas to several chemotherapeutics agents after knocking down PDIA3 (Ménoret et al., 2012) . Finally, PDIs were detected in a proteomic search for proteins altered by resveratrol. This drug was found to decrease the association between PDIA3 and several proteins (including transformation/transcription domain-associated protein, a potent c-myc co-factor) and increase in others (including a, b, and g catenin) (Xiong et al., 2012) . PDIA6 gene expression was lower in the group that was negative for hormonal receptors. It is well known that estrogen signaling is a contributing factor in the regulation of breast cell proliferation and that estrogen receptor targeting is a successful treatment for breast cancer. PDI shares homology with the estrogen-binding domain of estrogen receptor a and acts as a molecular chaperone required for estrogen receptor a-mediated gene regulation. As an estrogen-binding protein, PDI can modulate the level of estrogen released. Therefore, the level of PDI may be associated with the absence of hormone receptors, as observed in our study, which included a small sample size. Further studies including a larger number of samples should be conducted to confirm this hypothesis.
We observed higher expression of both genes in tumor samples compared with normal tissue, as well as in samples of patients with lymph node metastasis compared with samples of patients with no metastasis. PDIA3 expression was also increased in grade III tumors, indicating that it was altered in 2 important prognostic parameters. Our results suggest that PDI3 and PDI6 can be used as prognostic markers of aggressiveness. In addition, new therapeutic approaches can be developed using PDI inhibitors. Further studies are necessary to determine their functional properties and interactions with substrates and small chemical ligands.
